Brokerages expect Principia Biopharma Inc (NASDAQ:PRNB) to report ($0.74) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Principia Biopharma’s earnings. The highest EPS estimate is ($0.54) and the lowest is ($0.96). Principia Biopharma posted earnings of $0.37 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 300%. The firm is scheduled to issue its next earnings report on Tuesday, March 17th.
On average, analysts expect that Principia Biopharma will report full-year earnings of ($2.01) per share for the current financial year, with EPS estimates ranging from ($2.16) to ($1.77). For the next year, analysts expect that the business will post earnings of ($2.74) per share, with EPS estimates ranging from ($2.94) to ($2.31). Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for Principia Biopharma.
Principia Biopharma (NASDAQ:PRNB) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.85) by ($0.08). Principia Biopharma had a net margin of 11.88% and a negative return on equity of 11.95%.
PRNB traded up $1.77 during trading on Friday, hitting $57.00. The company’s stock had a trading volume of 4,491 shares, compared to its average volume of 305,957. The stock has a market capitalization of $1.69 billion, a price-to-earnings ratio of 98.95 and a beta of 1.37. Principia Biopharma has a 12 month low of $25.35 and a 12 month high of $61.07. The firm’s 50 day moving average price is $50.08 and its two-hundred day moving average price is $38.43.
In related news, Director Simeon George acquired 357,142 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The stock was acquired at an average cost of $31.12 per share, with a total value of $11,114,259.04. Also, insider Dolca Thomas sold 495 shares of Principia Biopharma stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $60.00, for a total value of $29,700.00. The disclosure for this sale can be found here. In the last 90 days, insiders have bought 489,742 shares of company stock valued at $15,515,759 and have sold 46,000 shares valued at $2,188,962. Insiders own 28.98% of the company’s stock.
Several institutional investors have recently made changes to their positions in PRNB. BlackRock Inc. raised its position in Principia Biopharma by 119.9% in the second quarter. BlackRock Inc. now owns 982,215 shares of the company’s stock worth $32,600,000 after acquiring an additional 535,495 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Principia Biopharma by 1.0% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 922,952 shares of the company’s stock valued at $30,633,000 after purchasing an additional 8,970 shares in the last quarter. Redmile Group LLC raised its holdings in shares of Principia Biopharma by 223.6% in the 3rd quarter. Redmile Group LLC now owns 790,006 shares of the company’s stock valued at $22,310,000 after purchasing an additional 545,906 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Principia Biopharma by 98.2% during the 2nd quarter. Vanguard Group Inc. now owns 574,862 shares of the company’s stock worth $19,079,000 after acquiring an additional 284,762 shares in the last quarter. Finally, Pictet Asset Management Ltd. bought a new position in shares of Principia Biopharma during the 3rd quarter worth approximately $7,898,000. 61.55% of the stock is owned by institutional investors and hedge funds.
Principia Biopharma Company Profile
Principia Biopharma Inc, a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura.
Featured Article: How To Calculate Debt-to-Equity Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Principia Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Principia Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.